An evidence-based osteopathic approach to Parkinson disease

Yao, Sheldon; Hart, Angela D.; Terzella, Michael J.

doi:10.1016/j.osfp.2013.01.003

Cited by 46 publications

(35 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Parkinson's disease (PD) is a common age-related neurodegenerative disease resulted from the progressive degeneration of dopaminergic neurons in the pars compacta region of substantia nigra [1][2][3][4]. The age at PD onset is approximately 55 years, and always occurs among old people with the incidence rising from 1% in the population aged >60 years to 4% in those aged >80 years [5,6]. Despite great advance in the understanding of PD pathophysiology, current therapy is unavailable for halting this neurodegenerative process [7].…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation

Peng

Liu

Wang

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Parkinson's disease (PD) is a common age-related neurodegenerative disease resulted from the progressive degeneration of dopaminergic neurons in the pars compacta region of substantia nigra. The goal of this study was to investigate the effects and mechanisms of long noncoding RNA (lncRNA) HAGLROS on the apoptosis and autophagy in PD. The MPTP-induced PD mouse model and MPP þintoxicated SH-SY5Y cell model were established, and the expression levels of HAGLROS and miR-100 were determined. Subsequently, the effects of suppression of HAGLROS on apoptosis and autophagy in MPTP-induced PD mouse model and in MPP þ-intoxicated SH-SY5Y cells were investigated. In addition, the association between HAGLROS and miR-100 as well as HAGLROS and activation of phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway in MPP þintoxicated SH-SY5Y cells was explored. HAGLROS was increasingly expressed in MPTP-induced PD mouse model and MPP þ-intoxicated SH-SY5Y cells and suppression of HAGLRO decreased apoptosis and autophagy in both in vivo and in vitro PD models. Further in vitro studies showed that HAGLRO negatively regulated miR-100 expression, and HAGLROS regulated apoptosis and autophagy of MPP þintoxicated SH-SY5Y cells through sponging miR-100. Moreover, ATG10 was identified as a target of miR-100. Besides, suppression of HAGLROS alleviated MPP þ-intoxicated SH-SY5Y cell injury by activating PI3K/AKT/mTOR pathway. Our findings reveal that upregulation of HAGLROS may contribute to the development of PD via inhibiting apoptosis and autophagy, which may be achieved by regulating miR-100/ATG10 axis and PI3K/AKT/mTOR pathway activation.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation

Peng

Liu

Wang

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Our sensor is thus sensitive enough to detect DA in this biological setting, especially when DA concentrations are low, e.g., in the central nervous system. This situation represents the usual clinical profile of a neurodegenerative disorder associated to Parkinson's disease (Yao et al, 2013), in which a major loss (4 80%) of dopaminergic neurons (responsible for DA production) is manifested (Spina et al, 1989). Based on these observations, we assume that the DA detection arises from a phosphorescent quenching process, which can be accounted for in terms of a pH dependent electron transfer from the QDs to oxidized dopamine quinone.…”

Section: Effect Of the Concentration Of Dopamine On The Phosphorescenmentioning

confidence: 97%

“…The US National Institute of Neurological Disorders classifies Parkinson's disease as the second most common neurodegenerative disorder, affecting approximately one million people in the US (Yao et al, 2013). This disease is related to the loss of brain cells that produce dopamine (DA).…”

Section: Introductionmentioning

confidence: 99%

L-cysteine capped ZnS:Mn quantum dots for room-temperature detection of dopamine with high sensitivity and selectivity

Diaz-Diestra

Thapa

Beltran‐Huarac

et al. 2017

Biosensors and Bioelectronics

121

View full text Add to dashboard Cite

Dopamine (DA) is one of the most important catecholamine neurotransmitters of the human central nervous system, and is involved in many behavioral responses and brain functions. Below normal DA levels in biological fluids can lead to different neurodegenerative conditions. For excess DA levels, a failure in energy metabolism is indicated. In this study, a facile room-temperature phosphorescence sensor is developed to detect DA based on l-cysteine capped Mn doped ZnS quantum dots (l-cys ZnS:Mn QDs). The QDs display a prominent orange emission band peaking at ~598nm, which is strongly quenched upon addition of DA in alkaline medium. The sensor exhibits a linear working range of ~0.15-3.00μM, and a limit of detection of ~7.80nM. These results are explained in terms of a pH-dependent electron transfer process, in which the oxidized dopamine quinone functions as an efficient electron acceptor. The QDs-based sensor shows a high selectivity to DA over common interfering biomolecules (including some amino acids, ascorbic acid, chloride and glucose). The sensor has been successfully applied for the detection of DA in urine samples, yielding recoveries as high as 93%. Our findings indicate that our developed sensor exhibits high sensitivity and reproducibility to determine DA even in biological fluids where DA is at low levels, e.g., in the central nervous system, which is the usual clinical profile of a neurodegenerative disorder associated to the Parkinson's disease.

show abstract

“…Only AD is more frequent than PD among the neurodegenerative disorders (Yao et al 2013;de Lau and Breteler 2006). PD frequency is about 0.3 % in industrialized countries and increases from 1 % in individuals older than 60 to 4 % in the population older than 80 (de Lau and Breteler 2006), with a mean age of onset of around 60; however, in 5-10 % of cases, it begins before 50 years of age (Samii et al 2004).…”

Section: Brain Neurons and Parkinson's Diseasementioning

confidence: 99%

Aging of perennial cells and organ parts according to the programmed aging paradigm

Libertini

Ferrara

2016

AGE

View full text Add to dashboard Cite

If aging is a physiological phenomenon-as maintained by the programmed aging paradigm-it must be caused by specific genetically determined and regulated mechanisms, which must be confirmed by evidence. Within the programmed aging paradigm, a complete proposal starts from the observation that cells, tissues, and organs show continuous turnover: As telomere shortening determines both limits to cell replication and a progressive impairment of cellular functions, a progressive decline in age-related fitness decline (i.e., aging) is a clear consequence. Against this hypothesis, a critic might argue that there are cells (most types of neurons) and organ parts (crystalline core and tooth enamel) that have no turnover and are subject to wear or manifest alterations similar to those of cells with turnover. In this review, it is shown how cell types without turnover appear to be strictly dependent on cells subjected to turnover. The loss or weakening of the functions fulfilled by these cells with turnover, due to telomere shortening and turnover slowing, compromises the vitality of the served cells without turnover. This determines well-known clinical manifestations, which in their early forms are described as distinct diseases (e.g., Alzheimer's disease, Parkinson's disease, age-related macular degeneration, etc.). Moreover, for the two organ parts (crystalline core and tooth enamel) without viable cells or any cell turnover, it is discussed how this is entirely compatible with the programmed aging paradigm.

show abstract

An evidence-based osteopathic approach to Parkinson disease

Cited by 46 publications

References 29 publications

RETRACTED ARTICLE: Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation

RETRACTED ARTICLE: Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation

L-cysteine capped ZnS:Mn quantum dots for room-temperature detection of dopamine with high sensitivity and selectivity

Aging of perennial cells and organ parts according to the programmed aging paradigm

Contact Info

Product

Resources

About